UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12b-25
NOTIFICATION OF LATE FILING 

Commission File Number: 000-50550 CUSIP Number: 05276J-20-3
 ---------- -----------
(Check One): [X] Form 10-K and Form 10-KSB [ ] Form 10-Q and Form 10-QSB
 [ ] Form 20-F [ ] Form 11-K [ ] Form N-SAR

For Period Ended: December 31, 2007
 ------------------------

[ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR

For the Transition Period Ended:

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Global Pharmatech, Inc.
Full Name of Registrant

Former Name if Applicable

509 Maoxiang Street
Address of Principal Executive Office (Street and Number)

High-Technology Industrial Development Zone, Changchun, Jilin, China 130012
City, State and Zip Code

PART II - RULES 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

[X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

[X] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why the Form 10-K and Form 10-KSB, 11-K, 20-F, 10-Q and Form 10-QSB, N-SAR, or other transition report or portion thereof, could not be filed within the prescribed period.

We could not file our Form 10-KSB on March 31, 2008 because our auditor has not finished auditing our financial report.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Mitchell S. Nussbaum, Esq. 212 407-4159
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), been filed? If answer is no, identify report(s). [X] YES [ ] NO

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statement to be included in the subject report or portion thereof?
[ ] YES [X] NO

If so, attach an explanation of the anticipated change, both narratively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Global Pharmatech, Inc.
(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. 

Date: March 31, 2008 By: /s/ Zongsheng Zhang
 -----------------------------------------
 Name: Zongsheng Zhang
 Title: Chief Financial Officer

LETTERHEAD OF MOORE STEPHENS, P.C.
CERTIFIED PUBLIC ACCOUNTANTS

March 31, 2008

Securities and Exchange Commission
450 Fifth Street, NW.
Washington, D.C. 20549

Ladies and Gentlemen:

We are retained by Global Pharmatech, Inc. (the "Company") as independent registered certified public accountants to report on the financial statements at December 31, 2007 and for the year then ended. We have endeavored, with the full cooperation of the Company, to obtain the necessary information to meet the filing requirements for Form 10-KSB, both as to form and timeliness. Due to the extensive period of time, and the related delay in developing data for the financial statements, we will not have sufficient time to complete our audit by March 31, 2008, which is the required filing date for the Company's annual report, without unreasonable effort and expense.

Very truly yours, 

/s/ Moore Stephens, P.C.
---------------------------------
Moore Stephens, P.C.

Global Pharmatech (PK) (USOTC:GBLP)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Global Pharmatech (PK) Charts.
Global Pharmatech (PK) (USOTC:GBLP)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Global Pharmatech (PK) Charts.